A perspective on automated advanced continuous flow manufacturing units for the upgrading of biobased chemicals toward pharmaceuticals.

Autor: Kaisin G; SynLock SRL, Rue de la Vieille Sambre 153, B-5190 Jemeppe-sur-Sambre, Belgium., Bovy L; Center for Integrated Technology and Organic Synthesis, Research Unit MolSys, University of Liège, B-4000 Liège, Sart Tilman, Belgium., Joyard Y; SynLock SRL, Rue de la Vieille Sambre 153, B-5190 Jemeppe-sur-Sambre, Belgium., Maindron N; SynLock SRL, Rue de la Vieille Sambre 153, B-5190 Jemeppe-sur-Sambre, Belgium., Tadino V; SynLock SRL, Rue de la Vieille Sambre 153, B-5190 Jemeppe-sur-Sambre, Belgium., Monbaliu JM; Center for Integrated Technology and Organic Synthesis, Research Unit MolSys, University of Liège, B-4000 Liège, Sart Tilman, Belgium.
Jazyk: angličtina
Zdroj: Journal of flow chemistry [J Flow Chem] 2022 Nov 29, pp. 1-15. Date of Electronic Publication: 2022 Nov 29.
DOI: 10.1007/s41981-022-00247-9
Abstrakt: Biomass is a renewable, almost infinite reservoir of a large diversity of highly functionalized chemicals. The conversion of biomass toward biobased platform molecules through biorefineries generally still lacks economic viability. Profitability could be enhanced through the development of new market opportunities for these biobased platform chemicals. The fine chemical industry, and more specifically the manufacturing of pharmaceuticals is one of the sectors bearing significant potential for these biobased building blocks to rapidly emerge and make a difference. There are, however, still many challenges to be dealt with before this market can thrive. Continuous flow technology and its integration for the upgrading of biobased platform molecules for the manufacturing of pharmaceuticals is foreseen as a game-changer. This perspective reflects on the main challenges relative to chemical, process, regulatory and supply chain-related burdens still to be addressed. The implementation of integrated continuous flow processes and their automation into modular units will help for tackling with these challenges.
Competing Interests: Competing interestsNo funding was received to assist with the preparation of this manuscript. Yoann Joyard, Geoffroy Kaisin and Nicolas Maindron are shareholders of the Company SynLock SRL. Vincent Tadino is a shareholder and the Executive Director of the Company SynLock SRL. Loic Bovy and Jean-Christophe M. Monbaliu have no relevant financial or non-financial interests to disclose.
(© Akadémiai Kiadó 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje